Last reviewed · How we verify
Lysosomal alpha-1,4-glucosidase deficiency - infantile onset
Approved treatments
- Myozyme · Genzyme, a Sanofi Company
- Rhgaa · Sanofi
Rhgaa works by replacing the deficient enzyme in patients with Pompe disease.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Lysosomal alpha-1,4-glucosidase deficiency - infantile onset patent landscape — cliff calendar, originator estates, attackable patents
- Lysosomal alpha-1,4-glucosidase deficiency - infantile onset treatment landscape brief
- Lysosomal alpha-1,4-glucosidase deficiency - infantile onset treatment updates RSS
Frequently asked questions about Lysosomal alpha-1,4-glucosidase deficiency - infantile onset
What drugs treat Lysosomal alpha-1,4-glucosidase deficiency - infantile onset?
Tracked treatments include Myozyme, Rhgaa.
What is the treatment for Lysosomal alpha-1,4-glucosidase deficiency - infantile onset?
Standard treatment for Lysosomal alpha-1,4-glucosidase deficiency - infantile onset includes Myozyme, Rhgaa. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Lysosomal alpha-1,4-glucosidase deficiency - infantile onset patent cliff · Lysosomal alpha-1,4-glucosidase deficiency - infantile onset CI report
- Treatment: Myozyme · Genzyme, a Sanofi Company
- Treatment: Rhgaa · Sanofi
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing